CULLINAN THERAPEUTICS, INC. Payments to Acquire Marketable Securities
CULLINAN THERAPEUTICS, INC. (CGEM) reported Payments to Acquire Marketable Securities of $448.55 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2021-11-09
- CULLINAN THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2021-09-30 was $85.30M, a 427.29% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2020-09-30 was $16.18M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month |
|---|---|---|---|
| 2021-09-30 | $85.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $448.55M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $363.25M 10-Q · filed 2021-08-10 | ||
| 2020-09-30 | $16.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $48.26M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $32.09M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |